Skip to main content
SpringerLink
Log in

Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751–761.

    Article  CAS  PubMed  Google Scholar 

  2. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol. 2003;1:89–95.

    Article  PubMed  Google Scholar 

  3. Tan S, Ayutyanont N, Bhattarai B, et al. Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. BMJ Open Gastroenterol. 2017;4:e000158.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.

    Article  PubMed  Google Scholar 

  5. Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis. 2008;12:425–443.

    Article  PubMed  Google Scholar 

  6. Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60:931–940.

    Article  CAS  PubMed  Google Scholar 

  7. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. September 21 2017.

  8. Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol. 2011;54:S13.

    Article  Google Scholar 

  9. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.

    Article  CAS  PubMed  Google Scholar 

  10. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.

    Article  CAS  PubMed  Google Scholar 

  11. Spacek LA, Solga SF. Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:e41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maricopa Medical Center, 2601 E Roosevelt Street, Phoenix, AZ, 85008, USA

    Gerard Quigley, Mustafa Al Ani & Abdul Nadir

Authors
  1. Gerard Quigley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Al Ani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdul Nadir
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have worked together in collecting data, reviewing medical literature, and writing up of this manuscript.

Corresponding author

Correspondence to Abdul Nadir.

Ethics declarations

Conflict of interest

The authors Abdul Nadir M.D., Gerard Quigley N.P., and Mustafa Al Ani M.D. certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Informed consent

Informed consent was obtained from the patient.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quigley, G., Al Ani, M. & Nadir, A. Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation. Dig Dis Sci 63, 529–532 (2018). https://doi.org/10.1007/s10620-017-4900-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4900-8

Keywords

Search

Navigation